Novartis2h
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.
Rolling Out5h
7 ways your lifestyle secretly disrupts hormonal balance
Discover natural approaches for hormonal balance at any age, from nutrition and sleep strategies to stress management ...
MedPage Today7h
Melatonin's Anti-Cancer Potential; Prenatal PFAS and Cancer; Anti-Viral Gel for HPV
A first-of-its-kind antiviral gel may offer the potential to stop papillomavirus (HPV) infection before it causes cancer. ( ...
precisionmedicineonline8h
CHMP Recommends Approval of AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Ultralow Breast Cancer
Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.
Where Does Breast Cancer Most Commonly Spread?
The peritoneal cavity, which contains the abdominal organs, is a less common but still potential site for breast cancer to ...
AstraZeneca Enhertu recommended for approval in EU by CHMP
Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...
AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...